Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21065478 | 0.82 | PNMT (0.39) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL21065635 | 0.77 | DRD2 (0.37) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL20889646 | 0.76 | CD44 (0.34) | PNMTCD44 | |
| SCHEMBL20883894 | 0.73 | HRH3 (0.38) | — | |
| SCHEMBL25085614 | 0.72 | PNMT (0.35) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL25060977 | 0.69 | MTNR1A (0.32) | — | |
| SCHEMBL23329957 | 0.69 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL7921103 | 0.69 | PNMT (0.55) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL21659168 | 0.67 | ASIC3 (0.35) | PNMT | |
| SCHEMBL8170304 | 0.67 | PNMT (0.48) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | PNMT 4730/4885CD44 328/4885MAOB 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.